p53 and Bcl-2expression in response to boldenone induced liver cells injury

Abstract

Boldenone is an anabolic steroid developed for veterinary use. Recently, it is used by bodybuilders in both off-season and pre-contest, where it is well known for increasing vascularity while preparing for a bodybuilding contest. So, the present study was designed to investigate the possible effect of using growth promoter boldenone undecylenate on the rabbit liver tissue. Thirty-two adult New Zealand rabbits were divided into four groups (8 animals each). Control group includes animals that injected intramuscularly with olive oil and dissected after 3 weeks. The experimental groups include animals that receive one, two and three intramuscular injections of 5 mg/kg body weight boldenone, respectively. The animals were dissected after 3, 6 and 9 weeks respectively, where the interval of each dose of boldenon was 3 weeks. Small pieces of the liver tissues were sent for the histopathological examination. Apoptotic p53 and antiapoptotic Bc1-2 proteins were localized immunohistochemically. Histological observations of the liver tissue showed that the sinusoidal congestion was the most prominent feature that extended from the centrilobular to the periportal regions. Hepatocellular vacuolation in the centrilobular region was also detected. Liver immunohistochemical observation showed a significant increase of the apoptotic protein p53 and a significant decrease in the antiapoptotic Bc1-2 proteins. The highest frequency of p53 positive cells was observed in the liver sections of three dose of boldenone injections, while the lowest in control group, also the highest frequency of Bcl-2 positive cells was observed in the liver sections of control group while the lowest in three dose of boldenone injections. The present results investigate that people should be careful if they want to use such steroids to enhance their strength and endurance.

Keywords

p53 and Bcl-2 expression apoptosis boldenone liver immunohistochemistry

Get full access to this article

View all access options for this article.

References

Appella E. ( 2001) ‘‘Modulation of p53 function in cellular regulation .’’ European Journal of Biochemistry 268(10): 2763.

Bahrke MS , Yesalis CE , Kopstein AN , and Stepkens JA ( 2000) Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Medicine 29: 397-405.

Bancroft JD and Cook HC ( 1994) Manual of Histological Techniques and their Diagnostic Application. 2nd ed. Edinburgh : Churchill Livingstone, 23-26.

Borner C. ( 2003) ‘‘The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions.’’ Molecular Immunology 39(11): 615-647.

Brookhouse B. ( 2007) Two More Positive Drug Tests. In Fight World’’. bloodyelbow.com. Available at http://www.bloodyelbow.com/story/2007/8/17/02615/9740

CannizzoTF, Zancanaro G. , Spada F. , Mulasso C. , Biolatti B. (2007) Pathology of the Testicle and Sex Accessory Glands Following the Administration of Boldenone and Boldione as Growth Promoters in Veal Calves. J Vet Med Sci 69(11): 1109-1116.

Collavin L. , Lunardi A. , and Del-Sal G. ( 2010) p43-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death and Differentiation 17: 901-911.

Cory S. and Adams JM ( 2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer 2: 647-656.

Alix F. De La Costa , McDonel N. , Porteu A. , Gilgenkrantz H. , Perret C. , Kahn A. , and Mignon A. ( 1999) Differential protective effects of Bcl-xL and Bcl-2 on apoptotic liver injury un transgenic mice. American Journal of Physiology-Gastrointestestinal and Liver Physiology 277(3): 702-708.

10.

Dickerman RD , Pertusi RM , Zachariah NY , Dufour DR , and McConathy WJ ( 1999) Anabolic steroidinduced hepatotoxicity: is it overstated ? Clinical Journal of Sports Medicine 9: 34-39.

11.

Forbes GB ( 1985) The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 34: 571-573.

12.

Gabr F. , Abo El-Maaty T. , Amal M. , and Aotifa AM ( 2009) Effects of growth promoter Boldenone undecylenate on weaned male lambs. Nature and Science 7(3): 61-69.

13.

Hartgens F. and Kuipers H. ( 2004) Effects of androgenic-anabolic steroids in athletes. Sports Medicine 34: 513-554.

14.

Haupt S. , Berger M. , Goldberg Z. , and Haupt Y. ( 2003) Apoptosis - the p53 network. Journal of Cell Science 116: 4077-4085.

15.

Hoffmann U. ( 2002) Anabolic steroids - a problem in popular sports. Toxichem Krimtech 69(3): 136-142.

16.

Hughes TK , Fulep E. , Juelich T. , Smith EM , and Stanton GJ ( 1995) Modulation of immune responses by anabolic androgenic steroids. International Journal of Immunopharmacology 17: 857-863.

17.

Jin S. and Levine AJ ( 2001) The p53 functional circuit. Journal of Cell Sciences 114: 4139- 4140.

18.

Kroemer G. , Zamzami N. , and Susin SA ( 1997) ‘‘Mitochondrial control of apoptosis. ’’ Immunology Today 18 (1): 44-51.

19.

Kuwana T. , Mackey M.R. , Perkins G. , Ellisman M.H. , Latterich M. , Schneiter R. , et al. (2002) Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111: 331-342.

20.

Kuhn CM ( 2002) Anabolic steroids. Recent Progress in Hormone Research 57: 411-434.

21.

Levine AJ ( 1997) p53, the cellular gatekeeper for geowth abd division. Cell 88: 323-331.

22.

Mooradian AD , Morley JE , and Korenman SG ( 1987) Biological actions of androgens. Endocrine Reviews 8: 1-28.

23.

Nagatu S. ( 1997) Apoptosis by death factor. Cell 88: 355-365.

24.

Rolland SG and Conradt B. ( 2010) New role of the BCL2 family of proteins in the regulation of mitochondrial dynamics. Current Opinion in Cell Biology 22(6): 852-858.

25.

Sader MA , Griffiths KA , McCredie RJ , Handelsman DJ , and Celermajer DS ( 2001) Androgenic anabolic steroids and arterial structure and function in male body builders. J American College of Cardiology 37: 224-230.

26.

Schänzer W. ( 1996) Metabolism of anabolic androgenic steroids. Clinical Chem 42: 1001-1020.

27.

Schänzer W. and Donike M. ( 1992) Metabolism of boldenone in man Gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates. Biological Mass Spectrometry 21: 3-16.

28.

Scorrano L. and Korsmeyer SJ ( 2003) ‘‘Mechanisms of cytochrome c release by proapoptotic BCL-2 family members.’’ Biochemical and Biophysical Research Communications 304(3): 437-44.

29.

Soma LR , Uboh CE , Guan F. , MC-Donnell S. , and Pack J. ( 2007) Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. Journal of Veterinary Pharmacology and Therapeutics 30: 101-108.

30.

Sternberger LA ( 1979) The unlabelled antibody peroxidase- antiperoxidase (PAP) method. In: Cohen S , McClusky RT (eds). Immunocytochemistry . 2nd ed. New York: John Wiley and sons, 104-169.

31.

Sullivan ML , Martinez CM , Gennis P. , and Gallagher EJ ( 1998) The cardiac toxicity of anabolic steroids. Progress in Cardiovascular Diseases 41: 1-15.

32.

Sundlof SF ( 2001) Legal control of veterinary drugs. In Adams HR (ed.) Veterinary Pharmacology Therapeutics. 8th edn, Ames, IA: Iowa State University Press, 1155.

33.

Vaux DL and Strasser (1996) The molecular biology of apoptosis. Proceedings of the National Academy of Sciences USA 93: 2239-2244.

34.

Teale P. and Houghton E. ( 1991) The development of a gas chromatographic/mass spectrometric screening procedure to detect the administration of anabolic steroids to the horse. Biological Mass Spectrometry 20: 109 114 .

35.

Thierry S. ( 2000) The p53 tumor suppressor gene: from molecular biology to clinical investigation. Annals of New York Academy of Sciences 910: 121-137.

36.

Welder AA , et al. (1995) Toxic effects of anabolic-androgenic steroids in primary rat hepatic cultures. Journal of Pharmacology and Toxicological Methods 33: 187-95.

37.

Yesalis CE , Bahrke MS , Kopstein AN , and Kennedy NJ ( 2000) Incidence of anabolic steroid use. A discussion of methodological issues. In: Yesalis CE (ed). Anabolic Steroids in Sport and Exercise. 2nd ed. Champaign, IL, 73-115.

38.

Yesalis CE , Kennedy NJ , Kopstein AN , and Bahrke MS ( 1993) Anabolic-androgenic steroid use in the United States. Journal of the American Veterinary Medical Association 270: 1217-1221.

39.

Yonish-Rouach E. , Grunwald D. , Wilder S. , Kimchi A. , May E. , Lawrence JJ , et al (1993) p53-mediated cell death: relationship to cell cycle control. Molecular Cell Biology 13: 1415-1423.

40.

Wang L. , Bowman L. , Lu Y. , Rojanasakul Y. , Mercer RR , Castranova V. , and Ding M. ( 2005) Essential role of p53 in silica-induced apoptosis. American Journal of Physiology 288: 488-496.